Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 26
20
Diseases
35
Unique genes
0.312
Avg. similarity score
Cervical lymphadenopathy
Most-connected disease (16 links)
Disease
Searched: Mixed germ cell tumor of central nervous system
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Mixed germ cell tumor of central nervous system
Cervical lymphadenopathy
Watson syndrome
Malignant peripheral nerve sheat tumor
Ganglioneuroma
Familial spinal neurofibromatosis
Cafe-au-lait spots
Glomus tumor
Middle aortic syndrome
Neurofibromatosis
17q11 microdeletion syndrome
Embryonal nuclear cataract
Melanoma, desmoplastic neurotrophic (2)neurofibromatosis, familial spinal
Neurofibromatosis type 1
Neurofibromatosis-noonan syndrome
Teratoma with malignant transformation
Legius syndrome
Small intestinal enteropathy-associated t-cell lymphoma
Collecting duct carcinoma
Moyamoya disease 2, susceptibility to
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Cervical lymphadenopathy | 16 | 16 | 1 |
| Watson syndrome | 16 | 16 | 1 |
| Malignant peripheral nerve sheat tumor | 15 | 15 | 1 |
| Ganglioneuroma | 12 | 12 | 1 |
| Familial spinal neurofibromatosis | 10 | 10 | 1 |
| Cafe-au-lait spots | 6 | 6 | 6 |
| Glomus tumor | 6 | 6 | 4 |
| Middle aortic syndrome | 6 | 6 | 4 |
| Neurofibromatosis | 6 | 6 | 4 |
| 17q11 microdeletion syndrome | 5 | 5 | 2 |
| Embryonal nuclear cataract | 5 | 5 | 6 |
| Melanoma, desmoplastic neurotrophic (2)neurofibromatosis, familial spinal | 5 | 5 | 1 |
| Mixed germ cell tumor of central nervous system | 5 | 5 | 2 |
| Neurofibromatosis type 1 | 5 | 5 | 1 |
| Neurofibromatosis-noonan syndrome | 5 | 5 | 4 |
| Teratoma with malignant transformation | 5 | 5 | 5 |
| Legius syndrome | 3 | 3 | 1 |
| Small intestinal enteropathy-associated t-cell lymphoma | 3 | 3 | 11 |
| Collecting duct carcinoma | 1 | 1 | 2 |
| Moyamoya disease 2, susceptibility to | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| NF1 | 17 / 20 | 17q11 microdeletion syndrome, Cafe-au-lait spots, Cervical lymphadenopathy, Embryonal nuclear cataract and 13 more |
| SPRED1 | 4 / 20 | Cafe-au-lait spots, Legius syndrome, Neurofibromatosis, Neurofibromatosis-noonan syndrome |
| TP53 | 3 / 20 | Collecting duct carcinoma, Embryonal nuclear cataract, Teratoma with malignant transformation |
| DICER1 | 2 / 20 | Embryonal nuclear cataract, Teratoma with malignant transformation |
| RNF213 | 2 / 20 | Middle aortic syndrome, Moyamoya disease 2, susceptibility to |
| SMARCB1 | 2 / 20 | Collecting duct carcinoma, Glomus tumor |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Chronic myeloid leukemia | KEGG | 8 / 77 | 35.7× | 4.03e-11 | 5.29e-9 ✓ sig. |
| Endocrine resistance | KEGG | 8 / 99 | 27.7× | 3.13e-10 | 3.27e-8 ✓ sig. |
| Non-small cell lung cancer | KEGG | 7 / 73 | 32.9× | 1.34e-9 | 1.21e-7 ✓ sig. |
| RAS signaling downstream of NF1 loss-of-function variants | Reactome | 4 / 7 | 196× | 2.10e-9 | 1.81e-7 ✓ sig. |
| Endometrial cancer | KEGG | 6 / 59 | 34.9× | 1.57e-8 | 1.11e-6 ✓ sig. |
| Downstream signal transduction | Reactome | 5 / 29 | 59.2× | 1.76e-8 | 1.22e-6 ✓ sig. |
| Acute myeloid leukemia | KEGG | 6 / 68 | 30.3× | 3.75e-8 | 2.37e-6 ✓ sig. |
| Neurotrophin signaling pathway | KEGG | 7 / 120 | 20.0× | 4.45e-8 | 2.75e-6 ✓ sig. |
| Renal cell carcinoma | KEGG | 6 / 70 | 29.4× | 4.48e-8 | 2.76e-6 ✓ sig. |
| Growth hormone synthesis, secretion and action | KEGG | 7 / 122 | 19.7× | 4.99e-8 | 3.03e-6 ✓ sig. |
| Thyroid cancer | KEGG | 5 / 37 | 46.4× | 6.36e-8 | 3.77e-6 ✓ sig. |
| Signaling by SCF-KIT | Reactome | 5 / 37 | 46.4× | 6.36e-8 | 3.77e-6 ✓ sig. |
| Glioma | KEGG | 6 / 76 | 27.1× | 7.37e-8 | 4.27e-6 ✓ sig. |
| EGFR tyrosine kinase inhibitor resistance | KEGG | 6 / 80 | 25.7× | 1.00e-7 | 5.61e-6 ✓ sig. |
| Bladder cancer | KEGG | 5 / 41 | 41.8× | 1.08e-7 | 6.01e-6 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of cell population proliferation | GO:0042127 | 8 / 201 | 21.3× | 2.86e-9 | 5.84e-7 ✓ sig. |
| MAPK cascade | GO:0000165 | 6 / 147 | 21.8× | 2.88e-7 | 3.07e-5 ✓ sig. |
| negative regulation of Schwann cell proliferation | GO:0010626 | 3 / 8 | 200× | 3.35e-7 | 3.49e-5 ✓ sig. |
| Ras protein signal transduction | GO:0007265 | 5 / 79 | 33.8× | 3.49e-7 | 3.60e-5 ✓ sig. |
| glial cell proliferation | GO:0014009 | 3 / 18 | 89.0× | 4.82e-6 | 3.08e-4 ✓ sig. |
| Schwann cell development | GO:0014044 | 3 / 20 | 80.1× | 6.71e-6 | 3.99e-4 ✓ sig. |
| negative regulation of cell-matrix adhesion | GO:0001953 | 3 / 22 | 72.8× | 9.05e-6 | 5.03e-4 ✓ sig. |
| Schwann cell proliferation | GO:0014010 | 2 / 3 | 356× | 1.02e-5 | 5.52e-4 ✓ sig. |
| forebrain astrocyte development | GO:0021897 | 2 / 3 | 356× | 1.02e-5 | 5.52e-4 ✓ sig. |
| negative regulation of cell migration | GO:0030336 | 5 / 190 | 14.1× | 2.61e-5 | 1.13e-3 ✓ sig. |
| negative regulation of non-canonical Wnt signaling pathway | GO:2000051 | 2 / 5 | 214× | 3.40e-5 | 1.38e-3 ✓ sig. |
| T cell differentiation in thymus | GO:0033077 | 3 / 41 | 39.1× | 6.11e-5 | 2.15e-3 ✓ sig. |
| regulation of MAPK cascade | GO:0043408 | 3 / 41 | 39.1× | 6.11e-5 | 2.15e-3 ✓ sig. |
| multicellular organism growth | GO:0035264 | 4 / 115 | 18.6× | 6.15e-5 | 2.16e-3 ✓ sig. |
| fibroblast proliferation | GO:0048144 | 3 / 42 | 38.1× | 6.57e-5 | 2.26e-3 ✓ sig. |